MannKind Corporation Reports 2015 Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
RBC Keeps MannKind (MNKD) at 'Underperform'; Afrezza Plans in Limbo Until CCO Hired
March 15, 2016 6:45 AM EDTRBC Capital reaffirms MannKind (Nasdaq: MNKD) at Underperform with a price target of $0.15 following Q4 results and update issued Monday night.
ANalyst Adnan Butt commented, While MNKD has an approved diabetes drug in its hands in Afrezza and technosphere platform could have value in future drug development, we would like to see execution on four fronts before... More
MannKind (MNKD) Posts Q4 Loss of 66c/Share
March 14, 2016 4:50 PM EDTMannKind (NASDAQ: MNKD) reported Q4 EPS of ($0.66), which may not compare with the analyst estimate of ($0.05).
Sales of Afrezza continued to be lower than expected during the fourth quarter of 2015, culminating in a decision by Sanofi on January 4, 2016 to return the... More
